GlassScriptPhysician profile
Lauren Aprn Lee
NPI 1972197101
$2,422.27
in general payments reported to CMS, 2019-2025
25 companies · $104 in 2025
The $104 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $731 · 2022: $844 · 2023: $660 · 2024: $82.70 · 2025: $104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $847.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $847.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $423.20 | 2021-2023 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $388.28 | 2021-2024 | Flumist Quadrivalent |
| Novo Nordisk INC | $346.47 | 2021-2023 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $310.57 | 2021-2023 | |
| Lilly USA, LLC | $175.92 | 2021-2023 | Mounjaro, Emgality, Reyvow |
| Bayer Healthcare Pharmaceuticals INC. | $88.77 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $77.90 | 2021-2023 | Trintellix |
| Novartis Pharmaceuticals Corporation | $63.39 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $52.00 | 2022 | |
| Axsome Therapeutics, INC. | $51.96 | 2022-2023 | Auvelity |
| Pfizer INC. | $51.64 | 2021-2022 | |
| Amarin Pharma, INC. | $45.46 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.91 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $36.90 | 2021-2022 | |
| Esperion Therapeutics, INC. | $35.32 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $32.02 | 2021 | |
| Merck Sharp & Dohme LLC | $30.72 | 2022-2025 | Keytruda, Keytruda Qlex |
| Janssen Biotech, INC. | $29.31 | 2025 | Balversa, Akeega, Erleada |
| Masimo Corporation | $23.55 | 2025 | Rainbow Acoustic Monitoring |
| Genentech USA, INC. | $23.24 | 2021 | |
| Glaxosmithkline, LLC. | $21.16 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.99 | 2022 | |
| Incyte Corporation | $18.17 | 2025 | Zynyz, Monjuvi |
| Dexcom, INC. | $16.78 | 2023 | Dexcom G6 Transmitter |
| Puma Biotechnology, INC. | $15.64 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.